An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results

Doody Rachelle S.; DAmico Stephen; Cutler Andrew J.; Davis Charles S.; Shin Paul; Ledon Fred; Yonan Charles; Siffert Joao

首页> 外文期刊>CNS spectrums >An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results

【24h】

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results

机译：在痴呆症中评估葡萄球菌/奎尼丁的安全性，耐受性和有效性的开放标签研究：PRISMI II结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background. Dextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness and tolerability for PBA secondary to dementia, stroke, or traumatic brain injury; dementia cohort results are reported.

机译：背景。甲吡咯（DM）/奎尼丁（Q）是基于肌萎缩侧面硬化或多发性硬化症中的试验的伪麻布影响（PBA）的批准治疗。棱镜II评估DM / Q次级痴呆，中风或创伤性脑损伤的PBA的有效性和耐受性; 报告了痴呆症队列结果。

著录项

来源
《CNS spectrums》 |2016年第6期|共10页
作者
Doody Rachelle S.; DAmico Stephen; Cutler Andrew J.; Davis Charles S.; Shin Paul; Ledon Fred; Yonan Charles; Siffert Joao;
展开▼
作者单位

Baylor Coll Med Houston TX 77030 USA;

Cornerstone Med Grp Franklin TN USA;

Florida Clin Res Ctr LLC Bradenton FL USA;

CSD Biostat Inc Tucson AZ USA;

Avanir Pharmaceut Inc Aliso Viejo CA USA;

Avanir Pharmaceut Inc Aliso Viejo CA USA;

Avanir Pharmaceut Inc Aliso Viejo CA USA;

Avanir Pharmaceut Inc Aliso Viejo CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类神经病学与精神病学;
关键词
Aged; Center for Neurologic Study-Lability Scale; dementia; dextromethorphan; global impression of change; neuropsychiatric symptoms; pseudobulbar affect; quinidine;

机译：岁;神经学研究中的中心;痴呆;糊擦;全球变化印象;神经精神症状;伪影响;奎尼丁;

相似文献

外文文献
中文文献
专利

1. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results [J] . Doody Rachelle S., DAmico Stephen, Cutler Andrew J., CNS spectrums . 2016,第6期

机译：在痴呆症中评估葡萄球菌/奎尼丁的安全性，耐受性和有效性的开放标签研究：PRISMI II结果
2. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect in Patients with Alzheimer's Disease/Dementia: PRISM-II [J] . Doody Rachelle S., DAmico Stephen, Cutler Andrew J., Annals of neurology . 2014,第Suppla18期

机译：右美沙芬/奎尼丁对阿尔茨海默氏病/痴呆症患者假性球病的安全性，耐受性和有效性：PRISM-II
3. Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study [J] . Flora M. Hammond, William Sauve, Fred Ledon, PM & R: the journal of injury, function, and rehabilitation . 2018,第10期

机译：葡萄球菌/奎尼丁的安全性，耐受性和有效性，用于创伤性脑损伤的研究参与者之间的影响：PRISM-II开放标签研究的结果
4. Pharmacokinetics and Tolerability of Sublingual Fentanyl in Healthy Japanese and Caucasian Volunteers: Phase I, Open-Label Single-Dose Study [C] . U. Lorch, F. Farrell, J. Kilborn, International Pain Clinic Congress . 2008

机译：健康日本和白种人志愿者舌下芬太尼的药代动力学和耐受性：I期，开放标签单剂量研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia stroke or traumatic brain injury [O] . Flora M. Hammond, David N. Alexander, Andrew J. Cutler, 2016

机译：勘误至：PRISM II：一项开放性研究评估右美沙芬/奎尼丁对痴呆中风或颅脑外伤患者的假性皮球影响
7. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results [O] . Rachelle S. Doody, Stephen D’Amico, Andrew J. Cutler, 2015

机译：在痴呆症中评估葡萄球菌/奎尼丁的安全性，耐受性和有效性的开放标签研究：PRISMI II结果

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results

摘要

著录项

相似文献

相关主题

期刊订阅